PCV26 ALL-Cause and Bleeding Costs of Patients Initiating P2Y12 Inhibitors, Fxa Inhibitors, and Dabigatran

Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.366
https://www.valueinhealthjournal.com/article/S1098-3015(21)00583-0/fulltext
Section Title :
Section Order : 10937
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00583-0&doi=10.1016/j.jval.2021.04.366
HEOR Topics :
Tags :
Regions :